表紙
市場調查報告書

神經性疼痛市場、預測分析

Neuropathic Pain Market and Forecast Analysis to 2026

出版商 Datamonitor Healthcare 商品編碼 633146
出版日期 內容資訊 英文 293 Pages
商品交期: 最快1-2個工作天內
價格
神經性疼痛市場、預測分析 Neuropathic Pain Market and Forecast Analysis to 2026
出版日期: 2018年10月23日內容資訊: 英文 293 Pages
簡介

本報告提供神經性疼痛市場相關調查分析,疾病定義與診斷,目前治療選項和未滿足需求,患者區分,及處方藥趨勢等相關彙整。

治療:神經性疼痛

  • 概要
  • 摘要整理
  • 一次調查手法
  • 疾病定義、診斷
  • 患者區分
  • 目前治療選項
  • 處方藥趨勢
  • 神經性疼痛的未滿足需求

流行病學:神經性疼痛

  • 概要
  • 疾病的背景
  • 調查手法
  • 預測
  • 參考資料

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: DMKC4922

Overview

Neuropathic pain is defined as pain caused by a lesion or disease of the somatosensory system, resulting in symptoms that include burning, stabbing, shooting, or electric shock-like sensations, which substantially differentiate it from nociceptive pain. Neuropathic pain is not a single disease, but a syndrome caused by an array of different diseases and lesions, with common subtypes such as diabetic peripheral neuropathy, post-herpetic neuralgia, and chemotherapy-induced neuropathic pain.

Market Snapshot

  • The opioid class is set to succeed anticonvulsants as market leader, as Lyrica faces generic competition in all markets.
  • Treatment of neuropathic pain has remained stagnant over recent years due to lack of innovation within the pain market.
  • The burden of neuropathic pain is difficult to estimate, but is likely high across all analyzed countries.
  • Lyrica continues to dominate neuropathic pain; however, revenues are set to fall dramatically following patent expiries.
  • Donaperminogene seltoplasmid is the only late-stage therapy to target the underlying cause of pain rather than symptoms.

TABLE OF CONTENTS

FORECAST: NEUROPATHIC PAIN (Published on 31 May 2018)

  • OVERVIEW
  • MARKET DYNAMICS
  • FORECAST AND FUTURE TRENDS
  • MARKET DEFINITION AND METHODOLOGY
  • PRIMARY RESEARCH METHODOLOGY
  • BIBLIOGRAPHY
  • PRODUCT PROFILE: CYMBALTA
  • PRODUCT PROFILE: GRALISE
  • PRODUCT PROFILE: LIDODERM
  • PRODUCT PROFILE: LYRICA
  • PRODUCT PROFILE: NUCYNTA ER
  • PRODUCT PROFILE (LATE STAGE): CEBRANOPADOL
  • PRODUCT PROFILE (LATE STAGE): DONAPERMINOGENE SELTOPLASMID
  • PRODUCT PROFILE (LATE STAGE): MIROGABALIN
  • PRODUCT PROFILE (LATE STAGE): RAXATRIGINE

TREATMENT: NEUROPATHIC PAIN (Published on 13 March 2018)

  • OVERVIEW
  • EXECUTIVE SUMMARY
  • PRIMARY RESEARCH METHODOLOGY
  • DISEASE DEFINITION AND DIAGNOSIS
  • PATIENT SEGMENTATION
  • CURRENT TREATMENT OPTIONS
  • PRESCRIBING TRENDS
  • UNMET NEEDS IN NEUROPATHIC PAIN

EPIDEMIOLOGY: NEUROPATHIC PAIN (Published on 23 October 2018)

  • OVERVIEW
  • DISEASE BACKGROUND
  • METHODOLOGY
  • FORECAST
  • BIBLIOGRAPHY

MARKETED DRUGS: NEUROPATHIC PAIN (Published on 31 May 2018)

  • OVERVIEW
  • PRODUCT OVERVIEW
  • PRODUCT PROFILE: CYMBALTA
  • PRODUCT PROFILE: GRALISE
  • PRODUCT PROFILE: LIDODERM
  • PRODUCT PROFILE: LYRICA
  • PRODUCT PROFILE: NUCYNTA ER

PIPELINE: NEUROPATHIC PAIN (Published on 31 May 2018)

  • OVERVIEW
  • CLINICAL PIPELINE OVERVIEW
  • ADDITIONAL PHARMA INTELLIGENCE PIPELINE RESOURCES
  • PRODUCT PROFILE (LATE STAGE): CEBRANOPADOL
  • PRODUCT PROFILE (LATE STAGE): DONAPERMINOGENE SELTOPLASMID
  • PRODUCT PROFILE (LATE STAGE): MIROGABALIN
  • PRODUCT PROFILE (LATE STAGE): RAXATRIGINE

LIST OF FIGURES

  • Figure 1: Neuropathic pain - current and future market dynamics analysis
  • Figure 2: Datamonitor Healthcare's assessment summary of key marketed and pipeline drugs for neuropathic pain
  • Figure 3: Neuropathic pain drug sales across the US, Japan, and five major EU markets, by country, 2017-26
  • Figure 4: Drug sales across the US, Japan, and five major EU markets, by drug class, 2017-26
  • Figure 5: Drug sales across the US, Japan, and five major EU markets, by neuropathic pain subtype, 2017-26
  • Figure 6: Methodology flow for Datamonitor Healthcare's neuropathic pain forecast
  • Figure 7: Price sources and calculations, by country
  • Figure 8: Cymbalta for neuropathic pain - SWOT analysis
  • Figure 9: Datamonitor Healthcare's drug assessment summary of Cymbalta for neuropathic pain
  • Figure 10: Datamonitor Healthcare's drug assessment summary of Cymbalta for neuropathic pain
  • Figure 11: Cymbalta sales for neuropathic pain disease across the US, Japan, and five major EU markets, by country, 2017-26
  • Figure 12: Gralise for neuropathic pain - SWOT analysis
  • Figure 13: Datamonitor Healthcare's drug assessment summary of Gralise for neuropathic pain
  • Figure 14: Datamonitor Healthcare's drug assessment summary of Gralise for neuropathic pain
  • Figure 15: Gralise sales for neuropathic pain in the US, 2017-26
  • Figure 16: Lidoderm for neuropathic pain - SWOT analysis
  • Figure 17: Datamonitor Healthcare's drug assessment summary of Lidoderm for neuropathic pain
  • Figure 18: Datamonitor Healthcare's drug assessment summary of Lidoderm for neuropathic pain
  • Figure 19: Lidoderm sales for neuropathic pain across the US, Japan, and five major EU markets, by country, 2017-26
  • Figure 20: Lyrica for neuropathic pain - SWOT analysis
  • Figure 21: Datamonitor Healthcare's drug assessment summary of Lyrica for neuropathic pain
  • Figure 22: Datamonitor Healthcare's drug assessment summary of Lyrica for neuropathic pain
  • Figure 23: Lyrica sales for neuropathic pain across the US, Japan, and five major EU markets, by country, 2017-26
  • Figure 24: Nucynta ER for neuropathic pain - SWOT analysis
  • Figure 25: Datamonitor Healthcare's drug assessment summary of Nucynta ER for neuropathic pain
  • Figure 26: Datamonitor Healthcare's drug assessment summary of Nucynta ER for neuropathic pain
  • Figure 27: Nucynta ER sales for neuropathic pain across the US, Japan, and major EU markets, by country, 2017-26
  • Figure 28: Cebranopadol for neuropathic pain - SWOT analysis
  • Figure 29: Datamonitor Healthcare's drug assessment summary of cebranopadol for neuropathic pain
  • Figure 30: Datamonitor Healthcare's drug assessment summary of cebranopadol for neuropathic pain
  • Figure 31: Cebranopadol sales for neuropathic pain across the five major EU markets, by country, 2017-26
  • Figure 32: Donaperminogene seltoplasmid for neuropathic pain - SWOT analysis
  • Figure 33: Datamonitor Healthcare's drug assessment summary of donaperminogene seltoplasmid for neuropathic pain
  • Figure 34: Datamonitor Healthcare's drug assessment summary of donaperminogene seltoplasmid for neuropathic pain
  • Figure 35: Donaperminogene seltoplasmid sales for neuropathic pain in the US, 2017-26
  • Figure 36: Mirogabalin for neuropathic pain - SWOT analysis
  • Figure 37: Datamonitor Healthcare's drug assessment summary of mirogabalin for neuropathic pain
  • Figure 38: Datamonitor Healthcare's drug assessment summary of mirogabalin for neuropathic pain
  • Figure 39: Mirogabalin sales for neuropathic pain in Japan, 2017-26
  • Figure 40: Raxatrigine for neuropathic pain - SWOT analysis
  • Figure 41: Datamonitor Healthcare's drug assessment summary of raxatrigine for neuropathic pain
  • Figure 42: Datamonitor Healthcare's drug assessment summary of raxatrigine for neuropathic pain
  • Figure 43: Raxatrigine sales for neuropathic pain across the US, Japan, and five major EU markets, by country ($m), 2017-26
  • Figure 44: Surveyed respondents' neuropathic pain patient caseload, by pain subtype
  • Figure 45: Surveyed respondents' neuropathic pain patient caseload, by pain severity
  • Figure 46: 2010 EFNS recommendations for neuropathic pain
  • Figure 47: Neuropathic pain pharmacological treatment rates, by pain subtype
  • Figure 48: Top five therapies among first-line painful diabetic peripheral neuropathy patients, by country (%)
  • Figure 49: Top five therapies among second-line and beyond painful diabetic peripheral neuropathy patients, by country (%)
  • Figure 50: Top five therapies among first-line post-herpetic neuralgia patients, by country (%)
  • Figure 51: Top five therapies among second-line post-herpetic neuralgia patients, by country (%)
  • Figure 52: Top five therapies among first-line chemotherapy-induced peripheral neuropathy patients, by country (%)
  • Figure 53: Top five therapies among second-line chemotherapy-induced peripheral neuropathy patients, by country (%)
  • Figure 54: Top five therapies among first-line post-herpetic neuralgia patients, by country (%)
  • Figure 55: Top five therapies among second-line other chronic neuropathic pain patients, by country (%)
  • Figure 56: Key unmet needs for neuropathic pain
  • Figure 57: Trends in total prevalent cases of neuropathic pain in the US, Japan, and five major EU markets, by country, 2017-37
  • Figure 58: Cymbalta for neuropathic pain - SWOT analysis
  • Figure 59: Datamonitor Healthcare's drug assessment summary of Cymbalta for neuropathic pain
  • Figure 60: Datamonitor Healthcare's drug assessment summary of Cymbalta for neuropathic pain
  • Figure 61: Cymbalta sales for neuropathic pain disease across the US, Japan, and five major EU markets, by country, 2017-26
  • Figure 62: Gralise for neuropathic pain - SWOT analysis
  • Figure 63: Datamonitor Healthcare's drug assessment summary of Gralise for neuropathic pain
  • Figure 64: Datamonitor Healthcare's drug assessment summary of Gralise for neuropathic pain
  • Figure 65: Gralise sales for neuropathic pain in the US, 2017-26
  • Figure 66: Lidoderm for neuropathic pain - SWOT analysis
  • Figure 67: Datamonitor Healthcare's drug assessment summary of Lidoderm for neuropathic pain
  • Figure 68: Datamonitor Healthcare's drug assessment summary of Lidoderm for neuropathic pain
  • Figure 69: Lidoderm sales for neuropathic pain across the US, Japan, and five major EU markets, by country, 2017-26
  • Figure 70: Lyrica for neuropathic pain - SWOT analysis
  • Figure 71: Datamonitor Healthcare's drug assessment summary of Lyrica for neuropathic pain
  • Figure 72: Datamonitor Healthcare's drug assessment summary of Lyrica for neuropathic pain
  • Figure 73: Lyrica sales for neuropathic pain across the US, Japan, and five major EU markets, by country, 2017-26
  • Figure 74: Nucynta ER for neuropathic pain - SWOT analysis
  • Figure 75: Datamonitor Healthcare's drug assessment summary of Nucynta ER for neuropathic pain
  • Figure 76: Datamonitor Healthcare's drug assessment summary of Nucynta ER for neuropathic pain
  • Figure 77: Nucynta ER sales for neuropathic pain across the US, Japan, and major EU markets, by country, 2017-26
  • Figure 78: Cebranopadol for neuropathic pain - SWOT analysis
  • Figure 79: Datamonitor Healthcare's drug assessment summary of cebranopadol for neuropathic pain
  • Figure 80: Datamonitor Healthcare's drug assessment summary of cebranopadol for neuropathic pain
  • Figure 81: Cebranopadol sales for neuropathic pain across the five major EU markets, by country, 2017-26
  • Figure 82: Donaperminogene seltoplasmid for neuropathic pain - SWOT analysis
  • Figure 83: Datamonitor Healthcare's drug assessment summary of donaperminogene seltoplasmid for neuropathic pain
  • Figure 84: Datamonitor Healthcare's drug assessment summary of donaperminogene seltoplasmid for neuropathic pain
  • Figure 85: Donaperminogene seltoplasmid sales for neuropathic pain in the US, 2017-26
  • Figure 86: Mirogabalin for neuropathic pain - SWOT analysis
  • Figure 87: Datamonitor Healthcare's drug assessment summary of mirogabalin for neuropathic pain
  • Figure 88: Datamonitor Healthcare's drug assessment summary of mirogabalin for neuropathic pain
  • Figure 89: Mirogabalin sales for neuropathic pain in Japan, 2017-26
  • Figure 90: Raxatrigine for neuropathic pain - SWOT analysis
  • Figure 91: Datamonitor Healthcare's drug assessment summary of raxatrigine for neuropathic pain
  • Figure 92: Datamonitor Healthcare's drug assessment summary of raxatrigine for neuropathic pain
  • Figure 93: Raxatrigine sales for neuropathic pain across the US, Japan, and five major EU markets, by country ($m), 2017-26

LIST OF TABLES

  • Table 1: Neuropathic pain drug sales across the US, Japan, and five major EU markets, by country ($m), 2017-26
  • Table 2: Drug sales across the US, Japan, and five major EU markets, by drug class ($m), 2017-26
  • Table 3: Drug sales across the US, Japan, and five major EU markets, by neuropathic pain subtype ($m), 2017-26
  • Table 4: Exchange rates used for calculating prices
  • Table 5: Primary care physicians and specialists surveyed for the neuropathic pain primary research study, 2017
  • Table 6: Therapies included within neuropathic pain key opinion leader discussions
  • Table 7: Cymbalta drug profile
  • Table 8: Cymbalta Phase III data in neuropathic pain syndromes
  • Table 9: Cymbalta sales for neuropathic pain across the US, Japan, and five major EU markets, by country ($m), 2017-26
  • Table 10: Gralise drug profile
  • Table 11: Gralise Phase III data in post-herpetic neuralgia
  • Table 12: Gralise sales for neuropathic pain in the US ($m), 2017-26
  • Table 13: Lidoderm drug profile
  • Table 14: Lidoderm Phase III data in neuropathic pain syndromes
  • Table 15: Lidoderm sales for neuropathic pain across the US, Japan, and five major EU markets, by country ($m), 2017-26
  • Table 16: Lyrica drug profile
  • Table 17: Lyrica Phase III data in diabetic neuropathy
  • Table 18: Lyrica Phase III data in post-herpetic neuralgia
  • Table 19: Lyrica sales for neuropathic pain across the US, Japan, and five major EU markets, by country ($m), 2017-26
  • Table 20: Nucynta ER drug profile
  • Table 21: Nucynta ER Phase III data in diabetic neuropathy
  • Table 22: Nucynta ER sales for neuropathic pain across the US, Japan, and major EU markets, by country ($m), 2017-26
  • Table 23: Cebranopadol drug profile
  • Table 24: Cebranopadol Phase II data in neuropathic pain
  • Table 25: Cebranopadol sales for neuropathic pain across the five major EU markets, by country ($m), 2017-26
  • Table 26: Donaperminogene seltoplasmid drug profile
  • Table 27: Donaperminogene seltoplasmid Phase II data in neuropathic pain
  • Table 28: Donaperminogene seltoplasmid Phase III trials in neuropathic pain
  • Table 29: Donaperminogene seltoplasmid sales for neuropathic pain in the US ($m), 2017-26
  • Table 30: Mirogabalin drug profile
  • Table 31: Mirogabalin Phase III data in neuropathic pain
  • Table 32: Mirogabalin Phase II data in neuropathic pain
  • Table 33: Mirogabalin sales for neuropathic pain in Japan ($m), 2017-26
  • Table 34: Raxatrigine drug profile
  • Table 35: Raxatrigine Phase II data in neuropathic pain
  • Table 36: Raxatrigine Phase III trials in neuropathic pain
  • Table 37: Raxatrigine sales for neuropathic pain across the US, Japan, and five major EU markets, by country ($m), 2017-26
  • Table 38: Primary care physicians and specialists surveyed for the neuropathic pain primary research study, 2017
  • Table 39: Therapies discussed in the neuropathic pain key opinion leader primary research study, December 2017
  • Table 40: Common neuropathic pain conditions and their etiology
  • Table 41: Treatments available for neuropathic pain across the US, Japan, and five major EU markets
  • Table 42: International Association for the Study of Pain recommendations
  • Table 43: Treatment strategies for painful diabetic peripheral neuropathy patients, by country (%)
  • Table 44: Treatment strategies for post-herpetic neuralgia patients, by country (%)
  • Table 45: Treatment strategies for chemotherapy-induced peripheral neuropathy, by country (%)
  • Table 46: Treatment strategies for other chronic neuropathic pain patients, by country (%)
  • Table 47: Compliance rates of neuropathic pain patients across the US, Japan, and five major EU markets, by therapy type and country
  • Table 48: Relative importance of unmet needs in neuropathic pain treatment in the US, Japan, and five major EU markets, by country
  • Table 49: Sources used for painful peripheral diabetic neuropathy analysis in the US, Japan, and five major EU markets
  • Table 50: Segmentation of total neuropathic pain patients by pain type, by country
  • Table 51: Total prevalent cases of neuropathic pain in the US, Japan, and five major EU markets, by country, 2017-37
  • Table 52: Profiled key marketed drugs for neuropathic pain
  • Table 53: Cymbalta drug profile
  • Table 54: Cymbalta Phase III data in neuropathic pain syndromes
  • Table 55: Cymbalta sales for neuropathic pain across the US, Japan, and five major EU markets, by country ($m), 2017-26
  • Table 56: Gralise drug profile
  • Table 57: Gralise Phase III data in post-herpetic neuralgia
  • Table 58: Gralise sales for neuropathic pain in the US ($m), 2017-26
  • Table 59: Lidoderm drug profile
  • Table 60: Lidoderm Phase III data in neuropathic pain syndromes
  • Table 61: Lidoderm sales for neuropathic pain across the US, Japan, and five major EU markets, by country ($m), 2017-26
  • Table 62: Lyrica drug profile
  • Table 63: Lyrica Phase III data in diabetic neuropathy
  • Table 64: Lyrica Phase III data in post-herpetic neuralgia
  • Table 65: Lyrica sales for neuropathic pain across the US, Japan, and five major EU markets, by country ($m), 2017-26
  • Table 66: Nucynta ER drug profile
  • Table 67: Nucynta ER Phase III data in diabetic neuropathy
  • Table 68: Nucynta ER sales for neuropathic pain across the US, Japan, and major EU markets, by country ($m), 2017-26
  • Table 69: Profiled pipeline products in development for neuropathic pain
  • Table 70: Cebranopadol drug profile
  • Table 71: Cebranopadol Phase II data in neuropathic pain
  • Table 72: Cebranopadol sales for neuropathic pain across the five major EU markets, by country ($m), 2017-26
  • Table 73: Donaperminogene seltoplasmid drug profile
  • Table 74: Donaperminogene seltoplasmid Phase II data in neuropathic pain
  • Table 75: Donaperminogene seltoplasmid Phase III trials in neuropathic pain
  • Table 76: Donaperminogene seltoplasmid sales for neuropathic pain in the US ($m), 2017-26
  • Table 77: Mirogabalin drug profile
  • Table 78: Mirogabalin Phase III data in neuropathic pain
  • Table 79: Mirogabalin Phase II data in neuropathic pain
  • Table 80: Mirogabalin sales for neuropathic pain in Japan ($m), 2017-26
  • Table 81: Raxatrigine drug profile
  • Table 82: Raxatrigine Phase II data in neuropathic pain
  • Table 83: Raxatrigine Phase III trials in neuropathic pain
  • Table 84: Raxatrigine sales for neuropathic pain across the US, Japan, and five major EU markets, by country ($m), 2017-26